Cargando…
The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats
Vascular ischemia/reperfusion injury (IRI) contributes to graft failure and adverse clinical outcomes following coronary artery bypass grafting. Sodium-glucose-cotransporter (SGLT)-2-inhibitors have been shown to protect against myocardial IRI, irrespective of diabetes. We hypothesized that adding c...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345991/ https://www.ncbi.nlm.nih.gov/pubmed/34360539 http://dx.doi.org/10.3390/ijms22157774 |
_version_ | 1783734761776218112 |
---|---|
author | Korkmaz-Icöz, Sevil Kocer, Cenk Sayour, Alex A. Kraft, Patricia Benker, Mona I. Abulizi, Sophia Georgevici, Adrian-Iustin Brlecic, Paige Radovits, Tamás Loganathan, Sivakkanan Karck, Matthias Szabó, Gábor |
author_facet | Korkmaz-Icöz, Sevil Kocer, Cenk Sayour, Alex A. Kraft, Patricia Benker, Mona I. Abulizi, Sophia Georgevici, Adrian-Iustin Brlecic, Paige Radovits, Tamás Loganathan, Sivakkanan Karck, Matthias Szabó, Gábor |
author_sort | Korkmaz-Icöz, Sevil |
collection | PubMed |
description | Vascular ischemia/reperfusion injury (IRI) contributes to graft failure and adverse clinical outcomes following coronary artery bypass grafting. Sodium-glucose-cotransporter (SGLT)-2-inhibitors have been shown to protect against myocardial IRI, irrespective of diabetes. We hypothesized that adding canagliflozin (CANA) (an SGLT-2-inhibitor) to saline protects vascular grafts from IRI. Aortic rings from non-diabetic rats were isolated and immediately mounted in organ bath chambers (control, n = 9–10 rats) or underwent cold ischemic preservation in saline, supplemented either with a DMSO vehicle (IR, n = 8–10 rats) or 50µM CANA (IR + CANA, n = 9–11 rats). Vascular function was measured, the expression of 88 genes using PCR-array was analyzed, and feature selection using machine learning was applied. Impaired maximal vasorelaxation to acetylcholine in the IR-group compared to controls was significantly ameliorated by CANA (IR 31.7 ± 3.2% vs. IR + CANA 51.9 ± 2.5%, p < 0.05). IR altered the expression of 17 genes. Ccl2, Ccl3, Ccl4, CxCr4, Fos, Icam1, Il10, Il1a and Il1b have been found to have the highest interaction. Compared to controls, IR significantly upregulated the mRNA expressions of Il1a and Il6, which were reduced by 1.5- and 1.75-fold with CANA, respectively. CANA significantly prevented the upregulation of Cd40, downregulated NoxO1 gene expression, decreased ICAM-1 and nitrotyrosine, and increased PECAM-1 immunoreactivity. CANA alleviates endothelial dysfunction following IRI. |
format | Online Article Text |
id | pubmed-8345991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83459912021-08-07 The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats Korkmaz-Icöz, Sevil Kocer, Cenk Sayour, Alex A. Kraft, Patricia Benker, Mona I. Abulizi, Sophia Georgevici, Adrian-Iustin Brlecic, Paige Radovits, Tamás Loganathan, Sivakkanan Karck, Matthias Szabó, Gábor Int J Mol Sci Article Vascular ischemia/reperfusion injury (IRI) contributes to graft failure and adverse clinical outcomes following coronary artery bypass grafting. Sodium-glucose-cotransporter (SGLT)-2-inhibitors have been shown to protect against myocardial IRI, irrespective of diabetes. We hypothesized that adding canagliflozin (CANA) (an SGLT-2-inhibitor) to saline protects vascular grafts from IRI. Aortic rings from non-diabetic rats were isolated and immediately mounted in organ bath chambers (control, n = 9–10 rats) or underwent cold ischemic preservation in saline, supplemented either with a DMSO vehicle (IR, n = 8–10 rats) or 50µM CANA (IR + CANA, n = 9–11 rats). Vascular function was measured, the expression of 88 genes using PCR-array was analyzed, and feature selection using machine learning was applied. Impaired maximal vasorelaxation to acetylcholine in the IR-group compared to controls was significantly ameliorated by CANA (IR 31.7 ± 3.2% vs. IR + CANA 51.9 ± 2.5%, p < 0.05). IR altered the expression of 17 genes. Ccl2, Ccl3, Ccl4, CxCr4, Fos, Icam1, Il10, Il1a and Il1b have been found to have the highest interaction. Compared to controls, IR significantly upregulated the mRNA expressions of Il1a and Il6, which were reduced by 1.5- and 1.75-fold with CANA, respectively. CANA significantly prevented the upregulation of Cd40, downregulated NoxO1 gene expression, decreased ICAM-1 and nitrotyrosine, and increased PECAM-1 immunoreactivity. CANA alleviates endothelial dysfunction following IRI. MDPI 2021-07-21 /pmc/articles/PMC8345991/ /pubmed/34360539 http://dx.doi.org/10.3390/ijms22157774 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Korkmaz-Icöz, Sevil Kocer, Cenk Sayour, Alex A. Kraft, Patricia Benker, Mona I. Abulizi, Sophia Georgevici, Adrian-Iustin Brlecic, Paige Radovits, Tamás Loganathan, Sivakkanan Karck, Matthias Szabó, Gábor The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats |
title | The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats |
title_full | The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats |
title_fullStr | The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats |
title_full_unstemmed | The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats |
title_short | The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats |
title_sort | sodium-glucose cotransporter-2 inhibitor canagliflozin alleviates endothelial dysfunction following in vitro vascular ischemia/reperfusion injury in rats |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345991/ https://www.ncbi.nlm.nih.gov/pubmed/34360539 http://dx.doi.org/10.3390/ijms22157774 |
work_keys_str_mv | AT korkmazicozsevil thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT kocercenk thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT sayouralexa thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT kraftpatricia thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT benkermonai thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT abulizisophia thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT georgeviciadrianiustin thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT brlecicpaige thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT radovitstamas thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT loganathansivakkanan thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT karckmatthias thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT szabogabor thesodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT korkmazicozsevil sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT kocercenk sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT sayouralexa sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT kraftpatricia sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT benkermonai sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT abulizisophia sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT georgeviciadrianiustin sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT brlecicpaige sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT radovitstamas sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT loganathansivakkanan sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT karckmatthias sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats AT szabogabor sodiumglucosecotransporter2inhibitorcanagliflozinalleviatesendothelialdysfunctionfollowinginvitrovascularischemiareperfusioninjuryinrats |